Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Peter Barrett Lee"'
Autor:
Wei Tan, Alastair Thompson, Alan Montgomery, Sarah Craig, Laura Ternent, Eleanor Mitchell, Lelia Duley, Ian Ellis, Alistair Ring, Nicole Francis, Hannah Price, David Dodwell, Elizabeth Miles, Rebecca Haydock, Margaret Childs, Mara Ozolins, Diane Whitham, Apostolos Fakis, David Whynes, Patricia Fairbrother, Robert Newcombe, Malcolm Reed, Daniel Davis, Tara Homer, Kathryn Monson, Ramsey Cutress, Valerie Jenkins, Lesley Fallowfield, Clare Brittain, Daniel Rea, Judith Bliss, Amit Goyal, G Bruce Mann, Robert E Coleman, Shabina Sadiq, Heath Badger, Rachel Helen Haines, Mickey Lewis, Daniel Megias, Zohal Nabi, Preetinder Singh, Andrei Caraman, Romaana Mir, Teresa Grieve, Clare Upton, Aisha Shafayat, Charlotte Gidman, Flonda Probert, Lisa Paksec, Rose Lucas, Annette Dempsey, Rochelle Thornton, Roeum Butt, Peter Barrett Lee, Julie Wolfarth, Peter Dubsky
Publikováno v:
BMJ Open, Vol 11, Iss 12 (2021)
Externí odkaz:
https://doaj.org/article/12460454e606498ebdb4b066396a1d8f
Autor:
Richard Clarkson, Julia Gee, Robert B. Clarke, Maria dM. Vivanco, Marco Piva, Fouad Alchami, Peter Barrett-Lee, Christine Morris, Philippa Young, Ladislav Andera, Iduna Fichtner, Michael Becker, Bruno M. Simões, Angelica Santiago-Gómez, Timothy Robinson, Andreia Silva, Luke Piggott
Figure S1: Endocrine-resistant MCF-7 cells demonstrate sensitivity to TRAIL Figure S2: Endocrine-resistant CSCs demonstrate sensitivity to TRIAL. Figure S3: Primary-derived patient samples. Figure S4: Endocrine-resistant primary and PDX tumour cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e19b7dfd3d8857d41b3de881fc5f24e
https://doi.org/10.1158/1078-0432.22465277
https://doi.org/10.1158/1078-0432.22465277
Autor:
Richard Clarkson, Julia Gee, Robert B. Clarke, Maria dM. Vivanco, Marco Piva, Fouad Alchami, Peter Barrett-Lee, Christine Morris, Philippa Young, Ladislav Andera, Iduna Fichtner, Michael Becker, Bruno M. Simões, Angelica Santiago-Gómez, Timothy Robinson, Andreia Silva, Luke Piggott
Purpose: One third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of unmet clinical need. Here, we identify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7526ee6a04e59ea6737bd64b7ddcc74a
https://doi.org/10.1158/1078-0432.c.6525980
https://doi.org/10.1158/1078-0432.c.6525980
Autor:
Ailsa J. Oswald, Stefan N. Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Karen McAdam, Peter Schmid, Simon Waters, Christopher Poole, Chris Twelves, Timothy Perren, John Bartlett, Tammy Piper, Eve Macdonald Chisholm, Michelle Welsh, Robert Hill, Lisa E. M. Hopcroft, Peter Barrett-Lee, David A. Cameron
Publikováno v:
Oswald, A, Symeonides, S N, Wheatley, D, Chan, S, Murray Brunt, A, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Macdonald Chisholm, E, Welsh, M, Hill, R, Hopcroft, L E, Barrett-Lee, P & Cameron, D A 2023, ' ARomatase Inhibition plus/minus Src-inhibitor SaracaTinib (AZD0530) in Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-023-06873-8
Purpose The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05748b6217c9d05f9fb0f6d40ba51272
https://hdl.handle.net/20.500.11820/9d500f76-cfbe-46d5-b5fc-dbc14bfd8050
https://hdl.handle.net/20.500.11820/9d500f76-cfbe-46d5-b5fc-dbc14bfd8050
Publikováno v:
Oncotarget
Introduction: Endocrine therapy has played an important role in the management of ER positive breast cancer over recent decades. Despite this, not all patients respond equally to endocrine intervention, which can lead to resistance, associated diseas
Autor:
Martin S. Hogg, Jean Tremlett, John Yarnold, Duncan Wheatley, K Venables, Ellen M. Donovan, Helen Passant, Peter Bliss, Joanna Bowen, Peter Barrett-Lee, Sri Kumar, Hafiz Algurafi, Joanne S Haviland, Adrian Harnett, D. Bloomfield, Y. Tsang, Abdulla Alhasso, Liz Sherwin, M. Sydenham, Judith M Bliss, R.K. Agrawal, Andy Goodman, Mary Quigley, A.M. Brunt, Isabel Syndikus, Alan L Stewart
Publikováno v:
Journal of Clinical Oncology. 38:3261-3272
PURPOSE Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcome
Autor:
Peter Barrett-Lee, S Waters, Eve Macdonald Chisholm, Chris Twelves, Peter Schmid, Michelle Welsh, Tammy Piper, Robert W. Hill, David Cameron, Murray Brunt, John M. S. Bartlett, Stefan Symeonides, Karen McAdam
Publikováno v:
Cancer Research. 80:P3-11
Background: Src, the first proto-oncogene to be described, is a non-receptor tyrosine kinase interacting with multiple oncogenic pathways, including cell proliferation, survival, angiogenesis and osteoclast activity. Src activation occurs in up to 40
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 4, Pp 552-558 (2018)
Purpose: This study aimed to explore the associations between dose-volume parameters of localized breast irradiation, longitudinal interleukin-6 soluble receptor (sIL-6R), and leukocyte counts as markers of an immune-mediated response and fatigue as
Autor:
Lucy Suzanne, Kilburn, Maria, Aresu, Jane, Banerji, Peter, Barrett-Lee, Paul, Ellis, Judith Margaret, Bliss
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-9 (2017)
Trials
Trials
Background Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants via routine da
Autor:
Ilaria Muller, Peter Barrett-Lee
Publikováno v:
Seminars in cancer biology. 64
The association between breast cancer and benign thyroid disorders, in particular thyroid autoimmunity, has been debated for decades. Autoantibodies to thyroid peroxidase, the hallmark of thyroid autoimmunity, have a higher prevalence among patients